Neurotransmitter-precursor-supplement intervention for detoxified heroin addicts

Abstract

This study examined the effects of combined administration of tyrosine, lecithin, L-glutamine and L-5-hydroxytryptophan (5-HTP) on heroin withdrawal syndromes and mental symptoms in detoxified heroin addicts. In the cluster-randomized placebo-controlled trial, 83 detoxified heroin addicts were recruited from a detoxification treatment center in Wuhan, China. Patients in the intervention group (n=41) were given the combined treatment with tyrosine, lecithin, L-glutamine and 5-HTP and those in the control group (n=42) were administered the placebo. The sleep status and the withdrawal symptoms were observed daily throughout the study, and the mood states were monitored pre- and post-intervention. The results showed that the insomnia and withdrawal scores were significantly improved over time in participants in the intervention group as compared with those in the control group. A greater reduction in tension-anxiety, depression-dejection, anger-hostility, fatigue-inertia and total mood disturbance, and a greater increase in their vigor-activity symptoms were found at day 6 in the intervention group than in the control group (all P<0.05). It was concluded that the neurotransmitter-precursor-supplement intervention is effective in alleviating the withdrawal and mood symptoms and it may become a supplementary method for patients’ recovery from heroin addiction.

Keywords

drug addiction / nutritional intervention / neurotransmitter precursors / withdrawal symptoms / mood

References

[1] CemekM., BüyükokuroğluM.E., Hazman, et al.. Antioxidant enzyme and element status in heroin addiction or heroin withdrawal in rats: effect of melatonin and vitamin E plus Se. Biol Trace Elem Res, 2011, 139(1): 41-45

[2] China National Narcotics Control Commission.. . Annual report on drug control in China, 2010, Beijing, Office of China National Narcotics Control Commission

[3] ZhaoL.Y., SunL.L., ShiJ., et al.. Effects of β-adrenergic receptor blockade on drug-related memory reconsolidation in abstinent heroin addicts. Drug Alcohol Depend, 2011, 118(2–3): 224-229

[4] LeshnerA.I.. Addiction is a brain disease, and it matters. Science, 1997, 278(5335): 45-47

[5] TomkinsD.M., SellersE.M.. Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence. CMAJ, 2001, 164(6): 817-821

[6] SaelandM., HaugenM., EriksenF.L., et al.. Living as a drug addict in Oslo, Norway-a study focusing on nutrition and health. Public Health Nutr, 2009, 12(5): 630-636

[7] Nazrul IslamS.K., Jahangir HossainK., AhmedA., et al.. Nutritional status of drug addicts undergoing detoxification: prevalence of malnutrition and influence of illicit drugs and lifestyle. Br J Nutr, 2002, 88(5): 507-513

[8] National Institute on Drug Abuse. Addiction science: from molecules to managed care. http://www.drugabuse.gov/pubs/teaching/Teaching6/Teaching4.html

[9] BlusztajnJ.K., WurtmanR.J.. Choline and cholinergic neurons. Science, 1983, 221(4611): 614-620

[10] MeyersS.. Use of neurotransmitter precursors for treatment of depression. Altern Med Rev, 2000, 5(1): 64-71

[11] WesterinkB.H., De VriesJ.B.. Effect of precursor loading on the synthesis rate and release of dopamine and serotonin in the striatum: a microdialysis study in conscious rats. J Neurochem, 1991, 56(1): 228-233

[12] ThomsonJ., RankinH., AshcroftG.W., et al.. The treatment of depression in general practice: a comparison of L-tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline with placebo. Psychol Med, 1982, 12(4): 741-751

[13] ZmilacherK., BattegayR., GastparM.. L-5-hydroxytry ptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression. Neuropsychobiology, 1988, 20(1): 28-35

[14] BravermanE.R.. . The edge effect: Achieve total health and longevity with the balanced brain advantage, 2005, New York, Sterling Publishing Co., Inc., NY, 8-164

[15] KoobG.F., Le MoalM.. Drug abuse: hedonic homeostatic dysregulation. Science, 1997, 278(5335): 52-58

[16] KennyP.J., ChenS.A., KitamuraO., et al.. Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J Neurosci, 2006, 26(22): 5894-5900

[17] SoldatosC.R., DikeosD.G., PaparrigopoulosT.J.. Athens insomnia scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res, 2000, 48(6): 555-560

[18] SunY., ChenX.. Standard measure of sleep quality. Chi Comm Doc (Chinese), 2002, 18(14): 15-16

[19] LiuC., XuG., ZhengJ.. Revision of rating scale for protracted withdrawal symptoms of heroin addicts. Chin J Drug Depend (Chinese), 2000, 9(2): 132-135

[20] ZhangZ.. . Handbook of behavioral medicine measuring scale, 2005, Beijing, Chinese Medical Multimedia Press, 238-239

[21] BousmanC.A., ChernerM., AkeC., et al.. Negative mood and sexual behavior among non-monogamous men who have sex with men in the context of methamphetamine and HIV. J Affect Disord, 2009, 119(1–3): 84-91

[22] ChungK.F., KanK.K., YeungW.F.. Assessing insomnia in adolescents: Comparison of insomnia severity index, athens insomnia scale and sleep quality index. Sleep Med, 2011, 12(5): 463-470

[23] Taylor-PiliaeR.E., MolassiotisA.. An exploration of the relationships between uncertainty, psychological distress and type of coping strategy among Chinese men after cardiac catheterization. J Adv Nurs, 2001, 33(1): 79-88

[24] LittellR.C., PendergastJ., NatarajanR.. Modelling covariance structure in the analysis of repeated measures data. Stat Med, 2000, 19(13): 1793-1819

[25] AhluwaliaJ.S., HarrisK.J., CatleyD., et al.. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA, 2002, 288(4): 468-474

[26] ZongL., LiangY., MuJ., et al.. Clinical investigation of protracted withdrawal symptoms in heroin addicts. Shanghai J Acu-mox, 2005, 24(9): 3-7

[27] Vashadze Sh V. Insomnia, serotonin and depression. Georgian Med News, 2007,(150):22–24

[28] LakhanS.E., VieiraK.F.. Nutritional therapies for mental disorders. Nutr J, 2008, 7: 2

[29] MaremmaniI., PaciniM., PaniP.P., et al.. The mental status of 1090 heroin addicts at entry into treatment: should depression be considered a ‘dual diagnosis’?. Ann Gen Psychiatry, 2007, 6: 31

[30] HasinD., LiuX., NunesE., et al.. Effects of major depression on remission and relapse of substance dependence. Arch Gen Psychiatry, 2002, 59(4): 375-380

[31] HodginsD.C., el-GuebalyN., ArmstrongS.. Prospective and retrospective reports of mood states before relapse to substance use. J Consult Clin Psychol, 1995, 63(3): 400-407

[32] AhmadiJ., MajdiB., MahdaviS., et al.. Mood disorders in opioid-dependent patients. J Affect Disord, 2004, 82(1): 139-142

[33] PelesE., SchreiberS., NaumovskyY., et al.. Depression in methadone maintenance treatment patients: rate and risk factors. J Affect Disord, 2007, 99(1–3): 213-220

[34] CohenB.M., MillerA.L., LipinskiJ.F., et al.. Lecithin in mania: a preliminary report. Am J Psychiatry, 1980, 137(2): 242-243

[35] CohenB.M., LipinskiJ.F., AltesmanR.I.. Lecithin in the treatment of mania: double-blind, placebo-controlled trials. Am J Psychiatry, 1982, 139(9): 1162-1164

[36] YoungS.N., GauthierS.. Effect of tryptophan administration on tryptophan, 5-hydroxyindoleacetic acid and indoleacetic acid in human lumbar and cisternal cerebrospinal fluid. J Neurol Neurosurg Psychiatry, 1981, 44(4): 323-328

[37] ChungS.Y., MoriyamaT., UezuE., et al.. Administration of phosphatidylcholine increases brain acetylcholine concentration and improves memory in mice with dementia. J Nutr, 1995, 125(6): 1484-1489

[38] JopeR.S.. Effects of phosphatidylcholine administration to rats on choline in blood and choline and acetylcholine in brain. J Pharmacol Exp Ther, 1982, 220(2): 322-328

[39] HirschM.J., WurtmanR.J.. Lecithin consumption increases acetylcholine concentrations in rat brain and adrenal gland. Science, 1978, 202(4364): 223-225